Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Paclitaxel|DRUG: Eribulin|DRUG: 5-Fluorouracil|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Doxorubicin
Sponsor: M.D. Anderson Cancer Center
Collaborators: Eisai Inc.